ahlam1399
02-23-2016, 08:34 PM
Valeant shares recover a bit after two-day slide
Feb 23 (Reuters) - Shares of Valeant Pharmaceuticals International Inc were up more than 6 percent in early U.S. trading on Tuesday following a two-day selloff, with some analysts saying that selling of the Canadian drugmaker's stock had been overdone.
http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/1/rc.img (http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/1/rc.htm)
http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/2/rc.img (http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/2/rc.htm)
http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/3/rc.img (http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/3/rc.htm)
http://da.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2.img (http://da.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2.htm)
http://adchoice.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/ach.img (http://adchoice.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/ach.htm)http://pi.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2t.imghttp://pi2.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4dcb0a07/sc/24/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=qugouJ-EcJA:zo3yXBcbSJ0:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=qugouJ-EcJA:zo3yXBcbSJ0:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=qugouJ-EcJA:zo3yXBcbSJ0:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=qugouJ-EcJA:zo3yXBcbSJ0:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=qugouJ-EcJA:zo3yXBcbSJ0:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/qugouJ-EcJA
Feb 23 (Reuters) - Shares of Valeant Pharmaceuticals International Inc were up more than 6 percent in early U.S. trading on Tuesday following a two-day selloff, with some analysts saying that selling of the Canadian drugmaker's stock had been overdone.
http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/1/rc.img (http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/1/rc.htm)
http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/2/rc.img (http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/2/rc.htm)
http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/3/rc.img (http://rc.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/rc/3/rc.htm)
http://da.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2.img (http://da.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2.htm)
http://adchoice.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/ach.img (http://adchoice.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/ach.htm)http://pi.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2t.imghttp://pi2.feedsportal.com/r/247392502517/u/49/f/654213/c/35217/s/4dcb0a07/sc/24/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4dcb0a07/sc/24/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=qugouJ-EcJA:zo3yXBcbSJ0:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=qugouJ-EcJA:zo3yXBcbSJ0:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=qugouJ-EcJA:zo3yXBcbSJ0:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=qugouJ-EcJA:zo3yXBcbSJ0:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=qugouJ-EcJA:zo3yXBcbSJ0:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/qugouJ-EcJA